Abstract: A corner joint for fenestration frames and the like includes first and second frame members having hollow interiors and ends joined in abutment. A corner key insert has legs inserted into the ends of the frame members. End portions of the legs engage the hollow interiors of the frame members forming adhesive cavities within the frame members and along the end portions of the corner key legs. Adhesive is disposed within the cavities to bond the corner key legs to the frame members, thereby creating a structural joint between the frame members. The corner key insert may include multiple injection ports for delivering adhesive to the cavities from a selected side of the frame assembly. Legs of the corner key may have notches formed therein to receive an internal wall of the frame members, and distal ends of the legs may include a flow barrier that contours along the notches.

Abstract: A guard for a tool. The tool is actuatable by a surgical device and has an elongated member and an energy applicator disposed at a distal end of the elongated member. The guard may have a monolithic body including a proximal end and a distal end opposite the proximal end. The proximal end connects to the surgical device. The body further has an interior surface defining a bore extending between the proximal and distal end and the bore adapted to receive the elongated member therethrough and an exterior surface extending between the proximal and distal end and encompassing the interior surface between the proximal and distal end. The body has at least one thermal mitigation channel located between the interior and exterior surfaces and opening through at least one port in the exterior surface.

Abstract: Some embodiments of the technology disclosed herein relate to a system having a hydrodynamic separator element defining an element inlet and an element outlet. The element outlet has a first element outlet and a second element outlet. The hydrodynamic separator element has a plurality of curved microfluidic channels in fluid communication. Each of the plurality of microfluidic channels are arranged to operate in parallel. Each microfluidic channel defines a channel inlet downstream of the element inlet and a channel outlet having a first channel outlet upstream of the first element outlet and a second channel outlet upstream of the second element outlet. A flow characteristic sensor is in sensing communication with the separator element. A controller is in data communication with the flow characteristic sensor, where the controller is configured to provide a first alert upon the flow characteristic being outside a first threshold.

Abstract: Robotic system and methods for preparing a bone of a joint to receive an implant. Virtual object(s) are used to define a volume of material to be removed from the bone for receipt of the implant. A robotic manipulator controls a cutting tool based on the virtual object(s) to form a first cavity and a second cavity in the bone. The second cavity is formed beneath the first cavity and is rotated relative to the first cavity to define an undercut in the bone. The first and second cavities receive a body and a locking member of the implant in an unlocked position. The locking member is rotated within the second cavity to a locked position whereby the undercut engages the locking member to limit withdrawal of the implant from the bone.

Abstract: A clamp assembly fixes a navigation tracker to a bone. The assembly includes first and second clamp jaws. The second clamp jaw is pivotal about a first fixed pivot. A linear driver includes a shaft. A first linkage is pivotal at one end about a second fixed pivot and coupled at an opposing end to the shaft at a first moving pivot. A second linkage is coupled at one end to the shaft at the first moving pivot and coupled at the other end to the second clamp jaw at a second moving pivot. The linear driver linearly translates the shaft to apply force to the first moving pivot in a first direction to pivot the second clamp jaw towards the first clamp jaw and in a second direction opposite to the first direction to pivot the second clamp jaw away from the first clamp jaw.

Abstract: The invention relates to heterocyclic compounds of the formula (I) in which all of the variables are as defined in the specification; capable of modulating the activity of CFTR. The invention further provides a method for manufacturing compounds of the invention, and its therapeutic uses. The invention further provides methods to their preparation, to their medical use, in particular to their use in the treatment and management of diseases or disorders including Cystic fibrosis and related disorders.

Abstract: The invention relates to heterocyclic compounds of the formula (I), in which all of the variables are as defined in the specification; capable of modulating the activity of CFTR. The invention further provides a method for manufacturing compounds of the invention, and its therapeutic uses. The invention further provides methods to their preparation, to their medical use, in particular to their use in the treatment and management of diseases or disorders including Cystic fibrosis and related disorders.

Abstract: The present invention provides compounds of Formula A: or a pharmaceutically acceptable salt, tautomer, or stereoisomer, thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds and methods of using such compounds for treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease caused by a parasite, such as leishmaniasis, human African trypanosomiasis and Chagas disease.

Abstract: The present invention provides compounds of Formula A: or a pharmaceutically acceptable salt, tautomer, or stereoisomer, thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds and methods of using such compounds for treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease caused by a parasite, such as leishmaniasis, human African trypanosomiasis and Chagas disease.

Abstract: The invention relates to heterocyclic compounds of the formula (I) in which all of the variables are as defined in the specification; capable of modulating the activity of CFTR. The invention further provides a method for manufacturing compounds of the invention, and its therapeutic uses. The invention further provides methods to their preparation, to their medical use, in particular to their use in the treatment and management of diseases or disorders including Cystic fibrosis and related disorders.